idarubicin has been researched along with pravastatin in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (60.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Appelbaum, FR; Banker, DE; Beran, M; Chen, W; Cortes, J; Estey, E; Estrov, Z; Faderl, S; Jackson, CE; Kornblau, SM; Lemker, E; Shen, D; Stirewalt, D; Verstovsek, S | 1 |
| Amin, HM; Harb, AJ; Quintás-Cardama, A; Verstovsek, S | 1 |
| Advani, AS; Appelbaum, FR; Copelan, E; List, AF; McDonough, S; Mulford, DA; Othus, M; Sekeres, MA; Willman, C | 1 |
| Becker, PS; Chen, TL; Dean, C; Estey, EH; Hendrie, PC; Mawad, R; Pagel, JM; Sandhu, V; Scott, BL; Shadman, M; Shannon-Dorcy, K; Walter, RB | 1 |
| Advani, AS; Appelbaum, FR; Erba, HP; Li, H; Liedtke, M; List, AF; Medeiros, BC; Michaelis, LC; O'Dwyer, K; Othus, M | 1 |
1 review(s) available for idarubicin and pravastatin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
4 trial(s) available for idarubicin and pravastatin
| Article | Year |
|---|---|
Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cholesterol; Cytarabine; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Pravastatin; Safety | 2007 |
SWOG0919: a Phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukaemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Pravastatin; Recurrence; Time Factors; Treatment Outcome; Young Adult | 2014 |
Idarubicin, cytarabine, and pravastatin as induction therapy for untreated acute myeloid leukemia and high-risk myelodysplastic syndrome.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Pravastatin; Risk Factors; Survival Rate | 2015 |
Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML).
Topics: Adult; Aged; Anticholesteremic Agents; Antineoplastic Combined Chemotherapy Protocols; Cholesterol; Cohort Studies; Combined Modality Therapy; Cytarabine; Cytogenetic Analysis; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Pravastatin; Recurrence; Remission Induction; Risk Factors; Survival Analysis; Treatment Outcome; Young Adult | 2018 |
5 other study(ies) available for idarubicin and pravastatin
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Granulocytic sarcoma with massive scalp involvement.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Back; Bone Marrow; Cytarabine; Daunorubicin; Fatal Outcome; Female; Humans; Idarubicin; Leukemic Infiltration; Meninges; Pravastatin; Sarcoma, Myeloid; Scalp; Skin | 2008 |